Academic Highlights: The Roadmap for Antipsychotic Psychopharmacology: An Overview [CME]
J Clin Psychiatry 2007;68(11):1799-1806
© Copyright 2015 Physicians Postgraduate Press, Inc.
Purchase This PDF for $40.00
If you are not a paid subscriber, you may purchase the PDF.
(You'll need the free Adobe Acrobat Reader.)
Receive immediate full-text access to JCP. You can subscribe to JCP online-only ($86) or print + online ($156 individual).
With your subscription, receive a free PDF collection of the NCDEU Festschrift articles. Hurry! This offer ends December 31, 2011.
If you are a paid subscriber to JCP and do not yet have a username and password, activate your subscription now.
As a paid subscriber who has activated your subscription, you have access to the HTML and PDF versions of this item.
Click here to login.
Did you forget your password?
Still can't log in? Contact the Circulation Department at 1-800-489-1001 x4 or send email
Because this piece does not have an abstract, we have provided for your benefit the first 3 sentences of the full text.
This article summarizes recommendations from a recently published supplement, Translating the Psychopharmacology of Antipsychotics to Individualized Treatment for Severe Mental Illness: A Roadmap.1 The President’s New Freedom Commission on Mental Health2 stressed the importance of incorporating the latest scientific information into mainstream health care as rapidly as possible. In keeping with this goal, the Roadmap drew on clinical trial data, information on antipsychotic pharmacology, practice guidelines,3–6 consensus statements,7 and expert opinion to develop recommendations for achieving best outcomes for individual patients.